Holen Sie sich die Stockscreener-App
181.28
3.39%
5.95
Handel nachbörslich:
181.28
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BDX?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$175.33
Offen:
$176.18
24-Stunden-Volumen:
1.89M
Relative Volume:
0.60
Marktkapitalisierung:
$51.96B
Einnahmen:
$20.87B
Nettoeinkommen (Verlust:
$1.50B
KGV:
34.60
EPS:
5.24
Netto-Cashflow:
$2.59B
1W Leistung:
+1.67%
1M Leistung:
+7.64%
6M Leistung:
-23.81%
1J Leistung:
-21.55%
1-Tages-Spanne:
$176.09
$181.63
1-Wochen-Bereich:
$175.31
$181.63
52-Wochen-Spanne:
$163.33
$251.99
Becton Dickinson Co Stock (BDX) Company Profile
Firmenname
Becton Dickinson Co
Sektor
Telefon
(201) 847-6800
Adresse
ONE BECTON DR, FRANKLIN LAKES
Vergleichen Sie BDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
181.28 | 51.10B | 20.87B | 1.50B | 2.59B | 5.24 |
|
ISRG
Intuitive Surgical Inc
|
511.00 | 183.59B | 8.71B | 2.48B | 1.75B | 6.82 |
|
ALC
Alcon Inc
|
88.66 | 42.51B | 9.93B | 1.12B | 1.58B | 2.25 |
|
RMD
Resmed Inc
|
267.40 | 36.95B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
218.90 | 15.88B | 2.90B | 467.20M | 306.90M | 6.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-02 | Herabstufung | Goldman | Buy → Neutral |
| 2025-05-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-05-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-05-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-01 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-05-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-05-30 | Eingeleitet | Goldman | Buy |
| 2023-07-24 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2023-05-30 | Fortgesetzt | Morgan Stanley | Overweight |
| 2023-05-05 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-04-12 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2023-01-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-12-12 | Hochstufung | Citigroup | Sell → Neutral |
| 2022-07-11 | Herabstufung | Citigroup | Neutral → Sell |
| 2022-06-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-03-18 | Fortgesetzt | Raymond James | Mkt Perform |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-08-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-25 | Eingeleitet | Barclays | Equal Weight |
| 2020-12-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-12-15 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-07-09 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-06-01 | Fortgesetzt | Goldman | Buy |
| 2020-03-05 | Eingeleitet | Citigroup | Neutral |
| 2020-02-07 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-02-07 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2020-02-07 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2020-02-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2020-01-08 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-05-13 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-12-07 | Eingeleitet | Deutsche Bank | Buy |
| 2018-10-16 | Eingeleitet | Barclays | Equal Weight |
| 2018-06-21 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2018-04-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-01-19 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-01-05 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-01-05 | Eingeleitet | KeyBanc Capital Mkts | Overweight |
| 2018-01-03 | Eingeleitet | Evercore ISI | Outperform |
| 2017-12-29 | Bestätigt | Deutsche Bank | Buy |
Alle ansehen
Becton Dickinson Co Aktie (BDX) Neueste Nachrichten
Jim Cramer Notes Becton Dickinson Stock Recently “Finished in the Black” - MSN
Becton Dickinson Biosciences & Diagnostics Unit to Merge With Waters Corp. in $17.5 Billion Deal - MSN
The Smartest Dividend Stock to Buy With $1,000 Right Now - The Motley Fool
Vascular Access Devices Company Evaluation Report 2025 | Becton Dickinson, Teleflex, and ICU Medical Strengthen Global Leadership Through Strategic Acquisitions and Product Innovation - Yahoo Finance
BD issues voluntary recall on certain Alaris infusion pump modules - MassDevice
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Announces Target Price $190 - 富途牛牛
Estimating The Fair Value Of Becton, Dickinson and Company (NYSE:BDX) - 富途牛牛
Morgan Stanley Maintains Becton Dickinson & Co(BDX.US) With Buy Rating, Maintains Target Price $196 - 富途牛牛
BD issues update to recall of Alaris & BD Alaris pump modules - MarketScreener
BD to spin off biosciences, diagnostics businesses in $17.5B deal (updated) - NJBIZ
Waters to acquire BD flow cytometry business in a deal valued at $17.5 billion - C&EN
Becton Dickinson and : BD Issues Update to Voluntary Global Recall of Alaris™ and BD Alaris™ Pump Modules Serviced with Legacy Bezel Kit Assemblies - MarketScreener
How Do Investors Really Feel About Becton Dickinson? - 富途牛牛
Becton Dickinson stock holds steady as TD Cowen maintains $183 price target By Investing.com - Investing.com South Africa
Becton Dickinson stock holds steady as TD Cowen maintains $183 price target - Investing.com Nigeria
Becton, Dickinson & Co (BDX) Is Paying a $85M Settlement to Investors — Here’s How to Get Your Share - TradingView
Becton, Dickinson and Company (BDX) Traded Down on Weak Earnings - Insider Monkey
Becton, Dickinson and Company: A Solid Divestment For Its Bioscience And Diagnostics Business - Seeking Alpha
Becton Dickinson’s Hold Rating Amid Strategic Moves and Limited Immediate Upside - TipRanks
TD Cowen Initiates Becton Dickinson & Co(BDX.US) With Hold Rating, Announces Target Price $183 - 富途牛牛
Waters, BD’s Biosciences & Diagnostic Solutions to combine - Medical Buyer
A Big Move By Waters Corporation And Becton, Dickinson And Company (NYSE:WAT) - Seeking Alpha
William Blair Maintains Becton Dickinson & Co(BDX.US) With Hold Rating - 富途牛牛
BD’s biosciences & diagnostics unit in $17.5B merger with Waters - BioWorld MedTech
$17.5B Deal Combines Waters with BD’s Biosciences and Diagnostics Business - Genetic Engineering and Biotechnology News
Becton Dickinson Announces Reverse Morris Trust with Waters - TipRanks
Becton Dickinson Finds a Partner for Its Biosciences and Diagnostics Business in Waters - Morningstar
Milford’s Waters Corp. strikes $17.5 billion deal to merge with BD’s diagnostics unit - The Boston Globe
Waters to buy Becton Dickinson unit in a $17.5 billion deal amid tariff pressures - CNBC
Waters, BD Unite in $17.5B Diagnostics Deal - USA Herald
Waters, BD Biosciences & Diagnostic Solutions to combine in $17.5B deal - MassDevice
Analytics Equipment Maker Waters Buys Becton Dickinson Unit in a $17.5B Deal - Investopedia
Waters inks $17.5B merger with division of BD - The Business Journals
Becton Dickinson Spins Off Biosciences In $17.5 Billion Waters Deal - Finimize
Here’s Why Becton, Dickinson and Company (BDX) Traded Lower in Q2 - MSN
Waters, BD Biosciences & Diagnostic Solutions to Merge in $17.5B Deal - Medical Product Outsourcing
Becton Dickinson gets its spinoff deal, but the stock is still falling - MSN
Why is Waters Stock Down On Monday?Becton Dickinson (NYSE:BDX), Waters (NYSE:WAT) - Benzinga
Becton, Dickinson and Company (BDX) Announces Strategic Merger w - GuruFocus
Waters and BD’s Biosciences & Diagnostic Solutions Business To Merge - citybiz
Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing - Placera.se
Becton Dickinson Unit to Combine With Waters Corp. in $17.5 Billion Deal - MarketScreener
Waters to Create $6.5B Life Sciences Giant Through $17.5B Merger with BD Biosciences Division - Stock Titan
Becton, Dickinson and Co. Advances with SiteRite 9 Ultrasound System Study - TipRanks
BD to acquire Bard - The Covington News
BD Appoints Bilal Muhsin as EVP and President of Future Connected Care Segment - citybiz
BD Appoints Bilal Muhsin as Executive Vice President and President of Future Connected Care Segment - MarketScreener
Wells Fargo Remains a Hold on Becton Dickinson (BDX) - The Globe and Mail
Becton, Dickinson and Co Completes Key Study on HPV Diagnostic Kit - TipRanks
Becton, Dickinson General Counsel to Be Medtronic Top Lawyer (1) - Bloomberg Law News
Becton, Dickinson and Co’s Latest Study on Male Incontinence Solutions: Market Insights - TipRanks
Finanzdaten der Becton Dickinson Co-Aktie (BDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):